Form 8-K - Current report:
SEC Accession No. 0001140361-26-019761
Filing Date
2026-05-08
Accepted
2026-05-08 09:01:19
Documents
11
Period of Report
2026-05-07
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K ny20072667x2_8k.htm   iXBRL 8-K 34463
  Complete submission text file 0001140361-26-019761.txt   164820

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA bbio-20260507.xsd EX-101.SCH 3868
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE bbio-20260507_lab.xml EX-101.LAB 21966
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bbio-20260507_pre.xml EX-101.PRE 16046
15 EXTRACTED XBRL INSTANCE DOCUMENT ny20072667x2_8k_htm.xml XML 4225
Mailing Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304
Business Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304 (650) 391-9740
BridgeBio Pharma, Inc. (Filer) CIK: 0001743881 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38959 | Film No.: 26956265
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)